A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was 'Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small cell lung cancer?'. Altogether over 318 papers were found, of which 18 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Stereotactic ablative radiotherapy (SABR) and sublobar resection (SLR) offer clear survival benefit in the treatment of early-stage non-small-cell lung cancer (NSCLC) in high-risk patients unsuitable for lobectomy and SABR has shown good results in medically operable patients. No randomized data are available comparing SLR and SABR, and therefore, data from prospective studies were compared. Overall survival at 1 year was similar between patients treated with SABR and SLR (81-85.7 vs 92%); however, overall 3-year survival was higher following SLR (87.1 vs 45.1-57.1%). There was no statistically significant difference in local recurrence in patients treated with SABR compared with SLR (3.5-14.5 vs 4.8-20%). Both treatment modalities are associated with complications. Fatigue (31-32.6%), pneumonitis (2.1-12.5%) and chest wall pain (3.1-12%) were common following SABR; however, serious grade 3 and 4 toxicity were rare. Morbidity following SLR was reported between 7.3 and 33.7%. Thirty-day mortality following SABR was 0%, while predicted 30-day mortality following a lung resection, using the thoracoscore predictive model ranges between 1 and 2.6%. Treatment for early-stage NSCLC should be tailored to individual patients. SABR is an acceptable alternative to SLR in high-risk patients but comparative data are required.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In [high-risk surgical patients with early stage non-small cell lung cancer], is [stereotactic ablative radiotherapy] equivalent to [sublobar resection]? 
The use of risk-adapted SABR delivered in eight fractions of 7.5 Gy does not 
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BEST EVIDENCE TOPIC resection (SLR) for Stage I NSCLC. For high-risk surgical patients, the traditional approach is SLR; however, this approach is associated with increased local recurrence compared with lobectomy [2] . Primarily used in medically inoperable patients with peripheral tumours, SABR has demonstrated high tumour control rates (>90%) compared with conventional radiotherapy, with minimal toxicity. Local recurrence is similar to that following lobectomy and SABR has shown promise in high-risk surgical patients owing to a lower toxicity profile compared with SLR. SLR is an acceptable alternative to surgery in tumours <2 cm; however, lobectomy is superior in tumours >2 cm in medically operable patients [4] [5] [6] [7] . Fernando et al. [6] reported a 30-day mortality of 1.4% and a 90-day mortality of 2.7% following SLR ± brachytherapy. Grade 3+ adverse events occurred in 14.9 and 19.3% of patients following SLR alone at 30 and 90 days, respectively.
Birdas et al. [5] reported an overall-survival rate of 54.1%, P = 0.38, and a 4-year disease-free survival of 43%, P = 0.57, following SLR. Fernando et al. [6] documented local recurrence in 17.2% of those treated with SLR alone. Okada et al. [7] reported superior 5-year cancer-specific survival in those with tumours ≤20 mm who had undergone segmentectomy (96.7%) and concluded that wedge resection was not suitable for tumours >20 mm.
Keenan et al. [8] reported a 1-year survival of 92% and a 4-year survival of 62% following segmentectomy and concluded that segmental resection preserved pulmonary function without compromising survival. Koike et al. [9] reported higher survival rates following SLR compared with lobectomy (94% 1 year, 89.1% 5 years). Zemlyak et al. [10] reported a 3-year cancer-specific survival of 90.6%, P < 0.05, following SLR.
Haasbeek et al. [11] investigated outcomes following SABR and reported a 3-year survival rate of 45% and actuarial 3-year local control was 89%. Timmerman et al. [12] reported a 3-year local control rate of 97.6% following SABR and an overall 3-year survival of 55.8%. Ricardi et al. [13] reported similar 3-year survival (57.1%). It should be noted that the survival of patients treated with SABR should be interpreted in the context of multiple comorbidities.
Fakiris et al. [14] reported lower toxicity in patients with peripheral tumours following SABR. However, there was no significant difference in survival between patients with peripheral and central tumours (P = 0.69).
Lagerwaard et al. [15] observed local recurrence in 3.5% of patients following SABR, which is much less than previously reported following conventional radiotherapy in Stage I NSCLC. Tumour stage was the only factor that significantly correlated with distant progression-free survival (P = 0.04). The most common adverse effects were fatigue (31%) and chest wall pain (12%). Le et al. [16] concluded that prior thoracic radiotherapy (doses ≥25 Gy) increased the risk of toxicity. SABR doses >20 Gy showed decreased local progression (9 vs 54%; P = 0.03) and higher complete response rates (57 vs 10%; P = 0.21) compared with <20 Gy. Onishi et al. [17] reported most benefit in patients with medically operable tumours, treated with BED ≥100 Gy. Timmerman et al. [18] found that SABR patients with perihilar/central tumours had an 11-fold increased risk of experiencing severe toxicity compared with more peripheral tumours. However, Haasbeek et al. [19] demonstrated that with a 'risk-adapted' strategy, central tumours could be treated safely. Tumours close to the left hemidiaphragm may be very dangerous to treat with SABR due to proximity to the stomach.
Puri et al. [20] investigated surgical resection and SABR. Median survival was higher in the surgical group (4.1 vs 2.9 years), as was 4-year survival (51.3 vs 30.1%). Surgical resection was more costeffective due to longer predicted overall survival. Grills et al. [21] reported a trend towards reduced local recurrence with SABR compared with wedge resection (4 vs 20%; P = 0.07).
An additional study not found in the PubMed search directly compared SLR and SBRT. Forquer et al. [22] compared outcomes between patients with Stage I NSCLC treated with SLR matched to those treated with SABR. There was no significant difference in 3-year survival between groups; however, SLR resulted in higher median survival (55 vs 37 months). Despite a higher rate of mortality in the SABR group, similar disease control and cancerspecific survival rates suggest that these treatments warrant direct comparison in patients who are not suitable for lobectomy but whose pulmonary function would allow SLR. SABR has similar outcomes, with low risk of toxicity and may avoid postoperative complications and extended stay in hospital. 
CLINICAL BOTTOM LINE
SLR and SABR are both reasonable alternatives to lobectomy in high-risk surgical patients. SABR is associated with reduced local recurrence (4 vs 20%; P = 0.07) and lower toxicity and should be considered when a wedge resection is planned due to anatomical location and size of the primary tumour in a patient who is highrisk for surgery. There is currently no clear consensus as to which treatment modality is better and ongoing trials are comparing SABR with surgery in this cohort of patients. Segmentectomy ± mediastinal lymph node dissection vs SABR and wedge resection ± brachytherapy vs SABR studies are needed to reach a firm conclusion on this debeatable topic.
